Thermo Fisher Scientific sets sights on Qiagen acquisition

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/Peskhova)
(Image: Getty/Peskhova)

Related tags: Thermo fisher, Technology, Laboratory, acquisition

The purchase is aimed at expanding the company’s specialty diagnostics offerings in sample preparation technology, assay capabilities, bioinformatics and more.

The corporate leaderships of Thermo Fisher Scientific and Qiagen NV have mutually approved the proposal to snap up the purchased company for $44.54 (£29.68) per share. The total value of the transaction stands at approximately $11.5bn (€10.1bn), including assumption of about $1.5bn (€1.3bn) of net debt.

Ron O’Brien, Thermo Fisher Scientific’s senior director, told Outsourcing-Pharma that his company’s global reach and structure will enable the benefits of Qiagen’s technology and capabilities to reach more organizations around the world.

This will ultimately benefit the Qiagen business, because Thermo Fisher has a way of doing things that tend to make the business operate more efficiently​,” he said.

Qiagen provides a range of life-science and molecular diagnostic technologies. Its staff includes about 5,100 employees at 35 sites in more than 25 countries. Its 2019 revenue was more than $1.5bn.

Thermo Fisher Scientific chairman, president and CEO Marc Casper said the company offers the company a chance to “advance our customers' important work.”

“This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs​,” he said.

The company’s sample preparation technologies are employed to extract, isolate and purify DNA, RNA and proteins from biological samples. Its assay technologies are used to make biomolecules accessible for analysis.

Thierry Bernard—Qiagen’s interim CEO, senior vice president and head of the molecular diagnostics business area—said the company’s mission of “making improvements in life possible​” will continue under Thermo Fisher’s ownership.

"This strategic step with Thermo Fisher will enable us to enter a promising new era and will give our employees the opportunity to have an even greater impact​,” he said.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us


View more